(C-81) A Large-Scale Characterization of AI Drug Development Companies

Several emerging computational biotechnology companies promise to reduce costs and accelerate drug development by applying state-of-the-art computational tools across various drug pipeline stage. Given the recent excitement for AI technology spurred by ChatGPT and other accessible generative AI tools, we anticipate strong public interest in these emerging computational drug development companies. Thus, we offer an analysis of company funding, positioning, and business strategies that highlights underdeveloped niches in the field and indicates potential high returns for companies that further develop their computational advantage. Overall, our insights can guide strategic investments in computational drug development to advance treatment of patients with computationally developed medications.